Human medicines European public assessment report (EPAR): Otezla, apremilast, Date of authorisation: 15/01/2015, Revision: 25, Status: Authorised

Guiding principles of good AI practice in drug development

New variations guidelines: webinar for marketing authorisation holders (human), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 13 January 2026, 13:00 (CET) to 13 January 2026, 15:00 (CET)

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Zvogra, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Abiraterone Accord, abiraterone, Date of authorisation: 26/04/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Stoboclo, denosumab, Date of authorisation: 14/02/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Date of authorisation: 21/04/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Date of authorisation: 12/02/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Rydapt, midostaurin, Date of authorisation: 18/09/2017, Revision: 14, Status: Authorised